RAS Inhibitors Market Size, Share, Growth Analysis 2023

The global ras inhibitors market size was valued at USD x billion in 2022 and is poised to grow at a significant CAGR of x% during the forecast period 2023-29. Ongoing research and development efforts in the RAS-inhibitors agents market are expanding its scope. New drugs targeting various renin-angiotensin system components, such as renin, ACE, and angiotensin II receptors, are being explored. The market is also witnessing increased interest in developing combination therapies that target multiple components simultaneously, aiming for better blood pressure control. Additionally, research into the use of RAS-acting agents for conditions beyond hypertension, including kidney disease and pulmonary hypertension, is driving the market growth. These advancements are fueling the expansion of the global RAS-inhibitors market.

View the detailed report description here https://www.precisionbusinessinsights.com/market-reports/ras-inhibitors-market

The global ras inhibitors market segmentation:
1) By Drug Class: ACE Inhibitors (Lisinopril, Enalapril, Ramipril), ARBs (Losartan, Valsartan, Candesartan),
2) By Renin Inhibitors: Telmisartan, Aliskiren, Moexipril
3) By Application: Hypertension, Heart Failure, Diabetic Nephropathy, and Others
4) By End-Use Industry: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

The hypertension segment anticipates the most in the global RAS inhibitors market. Hypertension, or high blood pressure, is widespread and requires long-term management. RAS inhibitors, such as ACE inhibitors and angiotensin receptor blockers (ARBs), are commonly prescribed for the treatment of hypertension. For instance, according to the World Health Organization (WHO), it is estimated that around 1.13 billion people globally have hypertension. This number is expected to increase due to various factors such as population growth, aging populations, unhealthy lifestyles, and dietary habits. The high prevalence of hypertension globally, coupled with the effectiveness of RAS inhibitors in managing this condition, contributes to the significant demand for RAS inhibitors in the hypertension segment. Additionally, the growing awareness about the importance of blood pressure control and the increasing emphasis on preventive healthcare further support the anticipated growth of the hypertension segment in the global RAS inhibitors market.

North America leads the RAS Inhibitors Market:
In North America, the RAS Inhibitors market holds a market share of XX% in 2022 and the market is expected to grow at a significant CAGR during the forecast period. The high incidence of hypertension-related deaths and the significant percentage of adults with uncontrolled hypertension in the United States indicate a growing need for renin inhibitors in the market. As hypertension prevalence continues to increase, the demand for renin inhibitors is expected to rise in this region. For instance, according to CDC data, hypertension was a primary or contributing cause in over 500,000 deaths in the United States in 2019. With approximately 116 million adults, or 47% of the population, diagnosed with hypertension and receiving medication, it highlights the significant prevalence of the condition. However, only around 24% of adults with hypertension have their condition effectively controlled. These statistics emphasize the need for improved management and treatment options for hypertension. As a result, the market for hypertension medications, including RAS inhibitors, is expected to grow in response to the increasing demand for effective therapies to address this widespread health concern.

Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=465844

Key players' profiles in the RAS Inhibitors Market report are Novartis AG, Pfizer, Inc., AstraZeneca plc, Merck & Co., Inc., Sanofi S.A., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Johnson & Johnson, Other Prominent Players.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.